Susquehanna Fundamental Investments LLC Sells 141,170 Shares of Pfizer Inc. (NYSE:PFE)

Susquehanna Fundamental Investments LLC cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 9.6% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,325,937 shares of the biopharmaceutical company’s stock after selling 141,170 shares during the quarter. Pfizer comprises about 0.9% of Susquehanna Fundamental Investments LLC’s investment portfolio, making the stock its 10th largest position. Susquehanna Fundamental Investments LLC’s holdings in Pfizer were worth $37,100,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in PFE. Wellington Management Group LLP grew its stake in shares of Pfizer by 4.9% during the 4th quarter. Wellington Management Group LLP now owns 239,209,768 shares of the biopharmaceutical company’s stock worth $6,886,849,000 after purchasing an additional 11,099,024 shares during the period. Marshall Wace LLP grew its stake in Pfizer by 279.3% in the 2nd quarter. Marshall Wace LLP now owns 5,378,173 shares of the biopharmaceutical company’s stock valued at $150,481,000 after acquiring an additional 8,378,173 shares during the last quarter. Swedbank AB acquired a new stake in Pfizer in the 1st quarter valued at about $172,902,000. Pzena Investment Management LLC grew its stake in Pfizer by 181.6% in the 1st quarter. Pzena Investment Management LLC now owns 7,670,445 shares of the biopharmaceutical company’s stock valued at $212,855,000 after acquiring an additional 4,947,000 shares during the last quarter. Finally, FIL Ltd grew its stake in Pfizer by 97.1% in the 4th quarter. FIL Ltd now owns 7,582,518 shares of the biopharmaceutical company’s stock valued at $218,301,000 after acquiring an additional 3,734,595 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Trading Up 0.5 %

Shares of PFE stock opened at $29.11 on Friday. The firm has a market cap of $164.95 billion, a P/E ratio of -485.17, a PEG ratio of 1.26 and a beta of 0.68. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $34.11. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The firm’s 50-day simple moving average is $29.32 and its 200-day simple moving average is $28.29.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.14. The business had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company’s revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.67 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.66 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently commented on PFE shares. Wells Fargo & Company increased their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Barclays raised their price target on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Finally, UBS Group raised their price target on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Eight analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.